03/16/2026
The weight returns. Here’s what your prescriber may not have told you.
The STEP 1 trial extension found that patients regained approximately two-thirds of their lost weight within one year of stopping semaglutide. SURMOUNT-4 showed similar trajectories with tirzepatide.
This is not surprising once you understand the mechanism.
GLP-1 receptor agonists work by suppressing appetite centrally, slowing gastric emptying, improving insulin sensitivity. both through weight loss and through direct receptor-mediated effects that can be detected within weeks of starting treatment.
These are powerful, well-documented benefits.But they are benefits that depend on continued treatment and continued weight maintenance.
When the medication stops and the weight returns, insulin sensitivity regresses with it. Ghrelin rises. Leptin resistance reasserts. The hypothalamus defends its set-point. The underlying metabolic environment (the chronic insulin resistance rooted in adipose dysfunction, ectopic fat deposition, and years of hyperinsulinemia ) has not been structurally resolved.
This is why pharmacotherapy alone produces a different long-term outcome than pharmacotherapy combined with a comprehensive metabolic strategy:
-Resistance training to protect lean mass and improve peripheral glucose uptake
-Nutrition structured around glycemic load and satiety signaling
-Behavioral work that addresses the neurobiological drivers of eating not “willpower.”
GLP-1 therapy is one of the most significant advances in obesity medicine in a generation. Used correctly, as part of a complete treatment plan, the outcomes are durable.
Used as a standalone intervention, the biology is predictable.
Save this if you’re currently on one of these medications share with a freind who needs to know this and follow me